<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although insulin-like growth factor 1 (IGF 1) has been used in immobilizated muscles to prevent <z:hpo ids='HP_0003202'>muscle atrophy</z:hpo>, its effects on <z:hpo ids='HP_0003202'>muscle atrophy</z:hpo> after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> are not known </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to determine the effects of IGF 1 on preventing <z:hpo ids='HP_0003202'>muscle atrophy</z:hpo> in rats with <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) was used to induce the <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In the first part of the study, rats were assigned to sham control, ischemic control, and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> with different dosages of IGF 1 injection groups to determine the optimal dosage of IGF 1 on preventing <z:hpo ids='HP_0003202'>muscle atrophy</z:hpo> after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In the second part of the study, rats were assigned to sham control, ischemic control, <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> with IGF 1, or with IGF 1 receptor inhibitor (AG1024) injection groups to determine the specificity of IGF 1 on preventing <z:hpo ids='HP_0003202'>muscle atrophy</z:hpo> after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>IGF 1 or AG1024 was injected locally to calf muscles and anterior tibialis (TA) starting from one day after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> and injections were carried out every other day for 4 times </plain></SENT>
<SENT sid="6" pm="."><plain>Muscle weight and myosin heavy chain (MHC) expression in both red (red gastrocnemius and soleus) and white (white gastrocnemius and TA) muscles were significantly decreased after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>With at least moderate-dosage (200 ng/100 microl PBS) IGF 1 injection, the muscle weight and MHC protein could be restored in both red and white muscles resulting in better motor performance </plain></SENT>
<SENT sid="8" pm="."><plain>However, the high-dose injection of IGF 1 (400 ng/100 microl PBS) did not result in further effects </plain></SENT>
<SENT sid="9" pm="."><plain>IGF 1 increased the expression of p-Akt, but such effects were prevented by AG1024 resulting in <z:hpo ids='HP_0003202'>muscle atrophy</z:hpo> and poor motor function </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, peripheral application of IGF 1 not only prevented <z:hpo ids='HP_0003202'>muscle atrophy</z:hpo> but also enhanced motor function in rats with <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The IGF 1-induced PI3K/Akt pathways are important for preventing <z:hpo ids='HP_0003202'>muscle atrophy</z:hpo> induced by <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
</text></document>